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Objective: Systemic sclerosis (SSc) is a connective tissue disorder characterized by the 
development of fibrosis in the skin and internal organs as well as microvascular dysfunction. 
There is growing evidences that vasculopathy-induced hypoxia and oxidative stress enhances 
the process of fibrosis in SSc. Tissue injury/hypoxia and oxidative stress induced-
extracellular ATP can act as a damage-associated molecular pattern molecules (DAMPs), 
which initiates inflammatory response. Regarding ATP and tissue fibrosis, several studies 
has been reported that extracellular ATP induced the development of fibrosis in several 
organs, such as heart, lung, liver and kidney. However, the role of ATP in the pathogenesis 
of skin fibrosis in SSc is unclear. Objective was to elucidate the role of extracellular ATP in 
skin fibrosis in Systemic sclerosis (SSc). 
Methods: ATP-induced IL-6 mRNA/protein levels in normal and SSc fibroblasts were 
compared. The effect of several antagonists of purinergic receptors and p38 inhibitors on 
ATP-induced IL-6 production in SSc fibroblasts were analysed. The effect of P2Y2 
purinergic receptor antagonist on Bleomycin-induced dermal fibrosis in mice was 
investigated.  
Results: We identified that hypoxia induced ATP release from SSc fibroblasts and normal 
human endothelial cells. In addition, we determined that ATP enhanced IL-6 production in 
normal and SSc fibroblasts, and that ATP-induced IL-6 production was significantly higher in 
SSc fibroblasts than in normal fibroblasts. The expressions of purinergic P2X and P2Y 
receptors were not changed between normal and SSc fibroblasts, suggesting that purinergic P2 
receptors expression might not be associated with the mechanisms underlying the higher ATP-
induced IL-6 production observed in SSc fibroblasts.  
Additionally, non-selective P2 receptor antagonist, Suramin, and P2Y2 receptor 
antagonist, Kaempferol and AR-C118925XX, significantly suppressed the ATP-induced IL-6 
production in SSc fibroblasts. ATP-induced IL-6 production was also significantly inhibited 
by p38 inhibitors, SB203580 and Doramapimod. These results suggest that ATP-induced 
phosphorylation of p38 via purinergic P2Y2 receptor might enhance IL-6 production in the 
SSc fibroblasts. Collagen type I production in SSc fibroblasts by ATP-induced IL-6/IL-6 
receptor trans-signaling was inhibited by Kaempferol and SB203580. These results suggest 
that ATP-induced IL-6 from dermal fibroblasts may have both paracrine and autocrine effects 
on dermal fibroblasts, T cells and B cells, and result in the skin fibrosis in SSc. Combined 
treatment with ATP and norepinephrine or ET-1 resulted in an additive increase in the 
production of IL-6 in the SSc fibroblasts. 
ATP is converted to AMP and adenosine by ectonucleotidase CD39 and CD73. We 
found that CD39 was not expressed in normal and SSc fibroblasts. In addition, CD73 and 
adenosine receptor expressions were not changed between normal and SSc fibroblasts. These 
results suggest that ATP-adenosine conversion may not be associated with ATP-induced IL-6 
production in SSc fibroblasts in vitro. 
We found that the amount of ATP in the mouse skin was significantly enhanced by 
injection of bleomycin for 7 days, and administration of Kaempferol, significantly inhibited 
Bleomycin-induced dermal fibrosis in mice. 
 
Conclusions: These results suggest that vasculopathy-induced hypoxia and oxidative stress 
might enhance ATP release in the dermis in SSc, and extracellular ATP-induced 
phosphorylation of p38 via P2Y2 receptor might enhance IL-6 and collagen type I production 
in SSc fibroblasts. P2Y2 receptor antagonists therapy could be an alternative treatment for skin 
sclerosis in patients with SSc. 
 
  
 
